These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38404173)

  • 1. Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan.
    Yoshida Y; Tozawa K; Koto R; Iwao C; Kim Y; Ban L; Barut V
    Curr Med Res Opin; 2024 Apr; 40(4):723-731. PubMed ID: 38404173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population.
    Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S
    Curr Med Res Opin; 2021 Sep; 37(9):1555-1561. PubMed ID: 34218725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas.
    Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S
    Pediatric Health Med Ther; 2020; 11():421-428. PubMed ID: 33117057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
    Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
    Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plexiform neurofibroma of the eye region occurring in patients without neurofibromatosis type 1.
    Bechtold D; Hove HD; Prause JU; Heegaard S; Toft PB
    Ophthalmic Plast Reconstr Surg; 2012; 28(6):413-5. PubMed ID: 22836801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.
    Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC
    Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
    Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
    Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
    Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
    Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
    Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
    Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
    Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
    Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study.
    Ejerskov C; Farholt S; Nielsen FSK; Berg I; Thomasen SB; Udupi A; Ågesen T; de Fine Licht S; Handrup MM
    Oncol Ther; 2023 Mar; 11(1):97-110. PubMed ID: 36454436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1.
    Tanito K; Ota A; Kamide R; Nakagawa H; Niimura M
    J Dermatol; 2014 Aug; 41(8):724-8. PubMed ID: 25041723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.
    Ahlawat S; Ly KI; Fayad LM; Fisher MJ; Lessing AJ; Berg DJ; Salamon JM; Mautner VF; Babovic-Vuksanovic D; Dombi E; Harris G; Plotkin SR; Blakeley J;
    Neurology; 2021 Aug; 97(7 Suppl 1):S111-S119. PubMed ID: 34230200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic delay of NF1 in hemifacial hypertrophy due to plexiform neurofibromas.
    Overdiek A; Feifel H; Schaper J; Mayatepek E; Rosenbaum T
    Brain Dev; 2006 Jun; 28(5):275-80. PubMed ID: 16481142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.